And recent changes to its pricing model indicate that it's looking for ways to expand its reach: ZocDoc announced early this year that it would be moving from a subscription model to a pay-per-booking structure, which should increase per-user revenue from its existing subscriber base in urban locations like New York, while also growing the company's footprint in rural areas where it can be difficult for clinicians to see enough patients for ZocDoc's services to make financial sense.

The company also enjoys 6 million monthly users. ZocDoc.The New York-based patient scheduling company has been operating since 2007 and is one of the most highly valued digital health companies around at nearly $2 billion in 2015, per Business Insider Prime reporting.Given Ancestry's consistent sales growth and the long-term potential of the DTC genetic testing industry, I think we're likely to see Ancestry go public by early next year. This figure tracks with the growth of genetic testing companies overall: The global at-home genetic testing market could reach over 100 million people by 2021 if current growth rates continue, according to the MIT Technology Review. When we first covered this story, we noted that Ancestry has sold approximately 14 million tests 4 million more than its closest competitor in the space, 23andMe and 7 million of those sales took place in just the last year. Ancestry.IPO rumors have swirled around Ancestry since April of this year, when inside sources told Bloomberg that the direct-to-consumer (DTC) genetic testing company was contemplating a public offering for the second half of 2019.

Zocdoc ipo 2021